近日,多个创新药或新适应症获美国食品药品监督管理局(FDA)批准,涉及罗氏、诺和诺德、勃林格殷格翰等。这些新药覆盖肿瘤、肥胖、肺纤维化等多个治疗领域,为患者带来了新的治疗选择。其中,罗氏近日公布,公司旗下CD20xCD3双特异性抗体Lunsumio VELO™(Mosunetuzumab,莫妥珠单抗)皮下注射剂型获FDA批准,适应症为用于治疗接受过至少两线系统治疗后复发或难治性(R/R)滤泡性...
Source Link近日,多个创新药或新适应症获美国食品药品监督管理局(FDA)批准,涉及罗氏、诺和诺德、勃林格殷格翰等。这些新药覆盖肿瘤、肥胖、肺纤维化等多个治疗领域,为患者带来了新的治疗选择。其中,罗氏近日公布,公司旗下CD20xCD3双特异性抗体Lunsumio VELO™(Mosunetuzumab,莫妥珠单抗)皮下注射剂型获FDA批准,适应症为用于治疗接受过至少两线系统治疗后复发或难治性(R/R)滤泡性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.